Reistone Biopharma

Privately held: no public share price

Assets

(3 total)
3Total Assets
0Approved
2Phase 3 / Filed
1Phase 1–2 / Early
4Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Phase 3
JAKSmall molecule
Non-Radiographic Axial Spondyloarthritis
Phase 3
Undisclosed / early pipelineSmall molecule
Atopic DermatitisPsoriasis
Phase 2
Undisclosed / early pipelineSmall molecule
Chronic Obstructive Pulmonary Disease

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
ivarmacitinibPhase 3Psoriatic Arthritis
Est. primary completion 2026-12-13 · NCT04957550 · CT.gov ↗
What to watch
2027 (2)
January 2027 (1)
RSS0393Phase 3Plaque Psoriasis Subjects
Est. primary completion 2027-01 · NCT07543224 · CT.gov ↗
What to watch
March 2027 (1)
ivarmacitinibPhase 2Non-segmental Vitiligo
Est. primary completion 2027-03 · NCT07251595 · CT.gov ↗
What to watch
2028 (1)
March 2028 (1)
RSS0343Phase 2Chronic Obstructive Pulmonary Disease
Est. primary completion 2028-03 · NCT07349524 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.